Liquidia Corporation will present data on LIQ861 at the PHPN Symposium in Seattle, focusing on pulmonary hypertension therapies.
Quiver AI Summary
Liquidia Corporation announced its participation in the Pulmonary Hypertension Professional Association (PHPN) Symposium from September 18 to 20, 2025, in Seattle, where it will present four posters related to its product, YUTREPIA™ (LIQ861). The company will showcase new safety and exploratory efficacy data from the ASCENT study focusing on patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Three additional posters will discuss YUTREPIA's effects on cardiac effort, quality of life, and device misuse scenarios. These presentations are scheduled for September 19, 2025, and will be accessible on Liquidia’s website after the session. YUTREPIA is an inhaled dry-powder formulation of treprostinil aimed at improving exercise ability for patients with pulmonary arterial hypertension and PH-ILD.
Potential Positives
- Liquidia Corporation will present new safety and exploratory efficacy data for LIQ861 at a prestigious symposium, highlighting its commitment to addressing unmet needs in pulmonary hypertension.
- The presentation of multiple posters at the Pulmonary Hypertension Professional Association (PHPN) Symposium demonstrates Liquidia's active engagement in research and its leadership in the field of cardiopulmonary diseases.
- YUTREPIA™ (LIQ861) is showcased as a novel treatment option with a focus on improving both exercise ability and quality of life for patients, reinforcing Liquidia's innovative approach in biopharmaceuticals.
Potential Negatives
- The announcement focuses on presenting exploratory efficacy data, which may suggest that the company is still in the early stages of validating the effectiveness of its treatment, potentially indicating a lack of established results.
- The reliance on previously published posters may imply that significant new findings are lacking, which could raise questions about the novelty and impact of their current research efforts.
- The press release does not provide any substantial updates on the commercialization timeline or regulatory progress for LIQ861, which may lead to investor concerns regarding the product's market entry and financial outlook.
FAQ
What is Liquidia Corporation presenting at the PHPN Symposium?
Liquidia will present four posters, including new safety and efficacy data on LIQ861 in PH-ILD patients.
When will Liquidia's poster presentations take place?
Poster presentations are scheduled for Friday, September 19, 2025, from 3:45 to 4:30 p.m. PT.
Where can I find the posters after the presentation?
Posters will be available on Liquidia’s Publications page at https://liquidia.com/publications.
What is YUTREPIA™?
YUTREPIA is an inhaled dry-powder formulation of treprostinil for treating pulmonary arterial hypertension and PH-ILD.
How does Liquidia's PRINT® technology benefit drug development?
PRINT® technology allows for precise and uniform drug particles, enhancing lung deposition after inhalation.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LQDA Insider Trading Activity
$LQDA insiders have traded $LQDA stock on the open market 46 times in the past 6 months. Of those trades, 0 have been purchases and 46 have been sales.
Here’s a breakdown of recent trading of $LQDA stock by insiders over the last 6 months:
- PAUL B MANNING has made 0 purchases and 4 sales selling 670,837 shares for an estimated $18,957,475.
- SCOTT MOOMAW (Chief Commercial Officer) has made 0 purchases and 7 sales selling 86,132 shares for an estimated $2,261,069.
- MICHAEL KASETA (CFO and COO) has made 0 purchases and 6 sales selling 85,499 shares for an estimated $1,666,714.
- ROGER JEFFS (Chief Executive Officer) has made 0 purchases and 4 sales selling 85,244 shares for an estimated $1,289,592.
- JASON ADAIR (Chief Business Officer) has made 0 purchases and 8 sales selling 35,897 shares for an estimated $884,868.
- RAJEEV SAGGAR (Chief Medical Officer) has made 0 purchases and 6 sales selling 41,614 shares for an estimated $882,681.
- RUSSELL SCHUNDLER (General Counsel) has made 0 purchases and 5 sales selling 24,246 shares for an estimated $382,726.
- RAMAN SINGH sold 7,500 shares for an estimated $220,650
- JOANNA HOROBIN sold 5,000 shares for an estimated $135,850
- SARAH KREPP (Chief Human Resource Officer) has made 0 purchases and 2 sales selling 2,882 shares for an estimated $44,241.
- DANA BOYLE (Chief Accounting Officer) has made 0 purchases and 2 sales selling 2,256 shares for an estimated $37,807.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LQDA Hedge Fund Activity
We have seen 104 institutional investors add shares of $LQDA stock to their portfolio, and 100 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LM ADVISORS LLC removed 2,206,443 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $32,545,034
- DEERFIELD MANAGEMENT COMPANY, L.P. added 1,616,778 shares (+inf%) to their portfolio in Q2 2025, for an estimated $20,145,053
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) added 1,616,778 shares (+inf%) to their portfolio in Q1 2025, for an estimated $23,847,475
- GOLDMAN SACHS GROUP INC added 1,555,774 shares (+180.6%) to their portfolio in Q2 2025, for an estimated $19,384,944
- TYRO CAPITAL MANAGEMENT LLC added 1,241,839 shares (+inf%) to their portfolio in Q2 2025, for an estimated $15,473,313
- VESTAL POINT CAPITAL, LP removed 1,227,403 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $15,293,441
- CENTERBOOK PARTNERS LP added 982,778 shares (+811.7%) to their portfolio in Q2 2025, for an estimated $12,245,413
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LQDA Analyst Ratings
Wall Street analysts have issued reports on $LQDA in the last several months. We have seen 7 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 08/15/2025
- Needham issued a "Buy" rating on 08/12/2025
- Wells Fargo issued a "Overweight" rating on 06/12/2025
- B of A Securities issued a "Buy" rating on 06/11/2025
- Scotiabank issued a "Sector Outperform" rating on 05/28/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/28/2025
- Oppenheimer issued a "Underperform" rating on 05/19/2025
To track analyst ratings and price targets for $LQDA, check out Quiver Quantitative's $LQDA forecast page.
$LQDA Price Targets
Multiple analysts have issued price targets for $LQDA recently. We have seen 8 analysts offer price targets for $LQDA in the last 6 months, with a median target of $35.5.
Here are some recent targets:
- Amy Li from Jefferies set a target price of $43.0 on 08/15/2025
- Ryan Deschner from Raymond James set a target price of $41.0 on 08/13/2025
- Tiago Fauth from Wells Fargo set a target price of $31.0 on 08/13/2025
- Serge Belanger from Needham set a target price of $36.0 on 08/12/2025
- Jason Gerberry from B of A Securities set a target price of $23.0 on 06/11/2025
- Andrew Fein from HC Wainwright & Co. set a target price of $35.0 on 05/28/2025
- Greg Harrison from Scotiabank set a target price of $37.0 on 05/28/2025
Full Release
MORRISVILLE, N.C., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present four posters at the Pulmonary Hypertension Professional Association (PHPN) Symposium taking place September 18 – 20, 2025, in Seattle.
In a live thematic poster session, Liquidia will highlight new safety and exploratory efficacy data pertaining to patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) who have participated in its fully enrolled ASCENT study of LIQ861 (YUTREPIA™) through Week 8. Liquidia will also present three previously published posters that highlight YUTREPIA’s impact on cardiac effort, its impact on quality of life and patient use of the device.
All posters will be presented on Friday, September 19, 2025 from 3:45 – 4:30 p.m. PT. Upon presentation, each poster will be available on the Publications page of Liquidia’s website at
https://liquidia.com/publications
.
Live Thematic Poster Session
Poster Discussion Session:
Poster Board #1037
Abstract:
A Continued ASCENT to Week 8: Initial Safety and Exploratory Efficacy Data on LIQ861 Dry Powder Inhaled Treprostinil in PH-ILD Patients
Encore Thematic Poster Sessions
Poster Discussion Session:
Poster Board #1041
Abstract:
Changes in Cardiac Effort in Pulmonary Hypertension-Interstitial Lung Disease: Insights from the ASCENT Trial
Poster Discussion Session:
Poster Board #1051
Abstract:
Quality of Life (QOL) in PAH Patients Receiving an Inhaled Dry Powder Treprostinil (LIQ861) in the INSPIRE Study
Poster Discussion Session:
Poster Board #1053
Abstract:
Robustness of LIQ861, a Dry-Powder Inhaled Formulation of Treprostinil, in Patient Misuse Scenarios
About YUTREPIA™ (treprostinil) Inhalation Powder
YUTREPIA is an inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. YUTREPIA is indicated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability. YUTREPIA was designed using Liquidia’s PRINT
®
technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. YUTREPIA was previously referred to as LIQ861 in investigational studies.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT
®
Technology. PRINT enabled the creation of Liquidia’s first approved product, YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit
www.liquidia.com
.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
[email protected]
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
[email protected]
